Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 5
2004 4
2005 2
2006 5
2007 1
2008 4
2009 5
2010 11
2011 5
2012 7
2013 10
2014 8
2015 10
2016 9
2017 7
2018 7
2019 7
2020 7
2021 5
2022 7
2023 6

Text availability

Article attribute

Article type

Publication date

Search Results

118 results

Results by year

Filters applied: . Clear all
Page 1
Role of immunotherapy in Ewing sarcoma.
Morales E, Olson M, Iglesias F, Dahiya S, Luetkens T, Atanackovic D. Morales E, et al. Among authors: atanackovic d. J Immunother Cancer. 2020 Dec;8(2):e000653. doi: 10.1136/jitc-2020-000653. J Immunother Cancer. 2020. PMID: 33293354 Free PMC article. Review.
Targeting the tumor microenvironment of Ewing sarcoma.
Morales E, Olson M, Iglesias F, Luetkens T, Atanackovic D. Morales E, et al. Among authors: atanackovic d. Immunotherapy. 2021 Dec;13(17):1439-1451. doi: 10.2217/imt-2020-0341. Epub 2021 Oct 21. Immunotherapy. 2021. PMID: 34670399 Review.
A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab.
Mikhael J, Belhadj-Merzoug K, Hulin C, Vincent L, Moreau P, Gasparetto C, Pour L, Spicka I, Vij R, Zonder J, Atanackovic D, Gabrail N, Martin TG, Perrot A, Bensfia S, Weng Q, Brillac C, Semiond D, Macé S, Corzo KP, Leleu X. Mikhael J, et al. Among authors: atanackovic d. Blood Cancer J. 2021 May 12;11(5):89. doi: 10.1038/s41408-021-00478-4. Blood Cancer J. 2021. PMID: 33980831 Free PMC article. Clinical Trial. No abstract available.
Elotuzumab as a novel anti-myeloma immunotherapy.
Radhakrishnan SV, Bhardwaj N, Steinbach M, Weidner J, Luetkens T, Atanackovic D. Radhakrishnan SV, et al. Among authors: atanackovic d. Hum Vaccin Immunother. 2017 Aug 3;13(8):1751-1757. doi: 10.1080/21645515.2017.1327487. Epub 2017 Jun 12. Hum Vaccin Immunother. 2017. PMID: 28604269 Free PMC article. Review.
Vaccine-induced T-cell responses against SARS-CoV-2 and its Omicron variant in patients with B cell-depleted lymphoma after CART therapy.
Atanackovic D, Luetkens T, Omili D, Iraguha T, Lutfi F, Hardy NM, Fan X, Avila SV, Saharia KK, Husson JS, Niederhaus SV, Margiotta P, Lee ST, Law JY, Mannuel HD, Vander Mause E, Bauman S, Lesho P, Hankey K, Baddley J, Kocoglu M, Yared JA, Rapoport AP, Dahiya S. Atanackovic D, et al. Blood. 2022 Jul 14;140(2):152-156. doi: 10.1182/blood.2022016175. Blood. 2022. PMID: 35537186 Free PMC article.
Immunotherapies targeting CD38 in Multiple Myeloma.
Atanackovic D, Steinbach M, Radhakrishnan SV, Luetkens T. Atanackovic D, et al. Oncoimmunology. 2016 Aug 5;5(11):e1217374. doi: 10.1080/2162402X.2016.1217374. eCollection 2016. Oncoimmunology. 2016. PMID: 27999737 Free PMC article. Review.
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
Mateos MV, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, Goldschmidt H, Larocca A, Chanan-Khan A, Sherbenou D, Avivi I, Benyamini N, Iida S, Matsumoto M, Suzuki K, Ribrag V, Usmani SZ, Jagannath S, Ocio EM, Rodriguez-Otero P, San Miguel J, Kher U, Farooqui M, Liao J, Marinello P, Lonial S; KEYNOTE-183 Investigators. Mateos MV, et al. Lancet Haematol. 2019 Sep;6(9):e459-e469. doi: 10.1016/S2352-3026(19)30110-3. Epub 2019 Jul 18. Lancet Haematol. 2019. PMID: 31327687 Clinical Trial.
Current Strategies for the Immunotherapy of Multiple Myeloma.
Luetkens T, Yousef S, Radhakrishnan SV, Atanackovic D. Luetkens T, et al. Among authors: atanackovic d. Oncology (Williston Park). 2017 Jan 15;31(1):55-63. Oncology (Williston Park). 2017. PMID: 28090624 Review.
The promise of adoptive cellular immunotherapies in hepatocellular carcinoma.
Hendrickson PG, Olson M, Luetkens T, Weston S, Han T, Atanackovic D, Fine GC. Hendrickson PG, et al. Among authors: atanackovic d. Oncoimmunology. 2019 Oct 13;9(1):1673129. doi: 10.1080/2162402X.2019.1673129. eCollection 2020. Oncoimmunology. 2019. PMID: 32002284 Free PMC article. Review.
118 results